In addition, as shown in Table 3, CX3CL1 levels were also increased in U87i lysates in BBB models with PBMCs from mild AD patients (6.69-fold) and moderate AD patients (10.34-fold) compared to U87i lysates in BBB models without PBMCs. Here, CX3CL1 is linked to Alzheimer disease.